SITC connectED Researcher Portal


Browse online courses and resources for researchers by cancer type, general immunotherapy courses, or click All Researcher Courses to view all available courses. Click the Additional Researcher Resources button to explore more SITC resources for researchers.


Collapse Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in Tumors

Access Course

 

538f50fa-48f9-4b55-a706-f9a2c75c85d9.jpgWhat are the implications for NSCLC, colorectal cancer, and other tumors?

This activity is intended for oncologists and pathologists.

The goal of this activity is to improve the adoption of evidence-based medicine by clarifying when the use of biomarkers is necessary to predict treatment response or when biomarkers do not inform practice.

 

 

Approximate Time to Complete: 40 minutes

 

Credit Available: March 29, 2017- March 29, 2018

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Original Course Date: March 29, 2017
MORE INFOMORE INFO Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in Tumors
Collapse Novel Concepts in the Management of RCC

Access Course

 

900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
 

This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

 

The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Sep. 19, 2018- Sep. 19, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Original Course Date: September 19, 2018
MORE INFOMORE INFO Novel Concepts in the Management of RCC
Collapse SITC 2017 Microlearning: Acquired Resistance Series

SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


The Acquired Resistance Series contains three modules. 

 

 

Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer

Katerina Politi, PhD - Yale School of Medicine


Module 2: Acquired Resistance to PD-1 Blockade in Melanoma

Antoni Ribas, MD, PhD - University of California, Los Angeles


Module 3: Acquired Resistance in Melanoma

Annette Paschen, MD - University Hospital Essen

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Original Course Date: August 16, 2018
MORE INFOMORE INFO SITC 2017 Microlearning: Acquired Resistance Series
Collapse SITC 2017 Microlearning: Additional Topics Series

Khaaliq_Thomas_SITC_2017_HS-8.jpgThe SITC 2017 Microlearning: Additional Topics Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


The SITC 2017 Microlearning: Additional Topics series contains three modules.

 

 

Module 1: Genetically Modified T Cells for Solid Tumors

Stephen Gottschalk, MD - St. Jude Children's Research Hospital


Module 2: Improvement in Epitope Discovery

Catherine J. Wu, MD - Dana-Farber Cancer Institute


Module 3: Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors

Vinod Balachandran, MD - Memorial Sloan Kettering Cancer Center

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Original Course Date: August 16, 2018
MORE INFOMORE INFO SITC 2017 Microlearning: Additional Topics Series
Collapse SITC 2017 Microlearning: Clinical Trials - New Agents Series

SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


The Clinical Trials - New Agents series contains four modules. 

 

 

Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

Peter Ellmark, PhD - Alligator Bioscience


Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents

James L. Gulley, MD, PhD, FACP - National Cancer Institute


Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

Glen J. Weiss, MD - Western Regional Medical Center Inc.


Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

Jason Williams, BS - University of Chicago

 

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Original Course Date: August 16, 2018
MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - New Agents Series
Collapse SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series

SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
 

The Clinical Trials - Novel Combinations series has three modules.

 

 

Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

Jose Saro, MD - Roche Innovation Center Zurich


Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

Zev Wainberg, MD - UCLA School of Medicine


Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

Douglas McNeel, MD, PhD - University of Wisconsin

 

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Original Course Date: August 16, 2018
MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series
Collapse SITC 2017 Microlearning: Toxicities Series

SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Toxicities Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


The Toxicities series contains three modules.

 

 

Module 1: Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis

Jennifer Wu, PhD - Northwestern University


Module 2: Pharmacological Management of irAEs

Nathan Dahl, PharmD, R.Ph, BCOP - Clovis Oncology


Module 3: Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool

Krista Marcello, BA - Clinical Care Options, LLC

 

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Original Course Date: August 16, 2018
MORE INFOMORE INFO SITC 2017 Microlearning: Toxicities Series


Researcher Courses by Cancer Type